Shimadzu Corporation will collaborate with clinical reagent manufacturer Sino Test Co., Ltd. (Chiyoda-ku, Tokyo) on the development of PCR test reagents in the field of infectious diseases. Through collaboration, both parties aim to enhance the lineup of test reagents used in real-time PCR devices such as our “genetic analysis device AutoAmp” (hereafter, AutoAmp).
Shimadzu Corporation has been developing reagents that enable simple and quick PCR testing using its proprietary technology “Ampdirect” since 1997. Since our in vitro diagnostic drug “Ampdirect 2019-nCoV detection kit” using “Ampdirect” does not require nucleic acid purification, it is possible to easily detect the novel coronavirus (SARS-CoV-2) by using PCR devices such as “AutoAmp,” which can perform PCR tests fully automatically. By combining PCR test reagent development technology using Sinotest with our “Ampdirect” and PCR devices, we will contribute to the expansion of the testing system for infectious diseases.
Synotest Co., Ltd. Overview
| CEO | ： | Tsukada Satoshi |
| Head office location | ： | 3-7-9 Kanda-Surugadai, Chiyoda-ku |
| Founding a business | ： | September 1951 |
| Business content | ： | Development, manufacture, and sale of clinical testing agents and devices |
| capital | ： | 140 million yen |
| number of employees | ： | 320 people |
| web site | ： |